Cargando…
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
HDACs are critical regulators of gene expression that function through histone modification. Non-histone proteins and histones are targeted by these proteins and the inhibition of HDACs results in various biological effects. Moreover, the aberrant expression and function of these proteins is thought...
Autores principales: | Imai, Yoichi, Hirano, Mitsuhito, Kobayashi, Masayuki, Futami, Muneyoshi, Tojo, Arinobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520917/ https://www.ncbi.nlm.nih.gov/pubmed/30987296 http://dx.doi.org/10.3390/cancers11040475 |
Ejemplares similares
-
CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia
por: Kaito, Yuta, et al.
Publicado: (2022) -
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
por: Hirano, Mitsuhito, et al.
Publicado: (2021) -
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
por: Futami, Muneyoshi, et al.
Publicado: (2017) -
The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells
por: Futami, Muneyoshi, et al.
Publicado: (2020) -
CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy
por: Meshitsuka, Sohsuke, et al.
Publicado: (2022)